(7-Methoxy-4,5-dihydropyrazolo[1,5-a]quinolin-3-yl)methanol | 1202520-52-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (7-Methoxy-4,5-dihydropyrazolo[1,5-a]quinolin-3-yl)methanol
• CAS: 1202520-52-2
• 化学式: C₁₃H₁₄N₂O₂
• 分子量: 230.266
• InChiKey: BRGVTQHULANWJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  47.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (7-Methoxy-4,5-dihydropyrazolo[1,5-a]quinolin-3-yl)methanol 在 2,2,6,6-四甲基哌啶氧化物 、 亚氨基二乙酸 作用下， 生成 7-Methoxy-4,5-dihydropyrazolo[1,5-a]quinoline-3-carbaldehyde
  参考文献：
  名称：

  The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties

  摘要：

  Amino-anthranilic acid derivatives have been identified as a new class of low serum shifted, high affinity full agonists of the human orphan G-protein-coupled receptor GPR109a with improved ADME properties. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.116
• 作为产物：
  描述：

  Ethyl 7-methoxy-4,5-dihydropyrazolo[1,5-a]quinoline-3-carboxylate 在 二异丁基氢化铝 、 盐酸 、 水 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 (7-Methoxy-4,5-dihydropyrazolo[1,5-a]quinolin-3-yl)methanol
  参考文献：
  名称：

  WO2007/75749

  摘要：

  公开号：

文献信息

• Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
  申请人：Colletti L. Steven

  公开号：US20070299101A1

  公开（公告）日：2007-12-27

  The present invention relates to niacin receptor agonists of formula: (I); as well as pharmaceutically acceptable salts and solvates. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.

  本发明涉及公式（I）的烟酸受体激动剂，以及药学上可接受的盐和溶剂。这些化合物对于治疗脂质代谢异常，特别是降低血清低密度脂蛋白（LDL）、超低密度脂蛋白（VLDL）和三酰甘油，并提高高密度脂蛋白（HDL）水平是有用的。还包括药物组合物和治疗方法。
• WO2007/75749
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of Novel Tricyclic Full Agonists for the G-Protein-Coupled Niacin Receptor 109A with Minimized Flushing in Rats
  作者：Hong C. Shen、Fa-Xiang Ding、Qiaolin Deng、Larissa C. Wilsie、Mihajlo L. Krsmanovic、Andrew K. Taggart、Ester Carballo-Jane、Ning Ren、Tian-Quan Cai、Tsuei-Ju Wu、Kenneth K. Wu、Kang Cheng、Qing Chen、Michael S. Wolff、Xinchun Tong、Tom G. Holt、M. Gerard Waters、Milton L. Hammond、James R. Tata、Steven L. Colletti

  DOI：10.1021/jm900151e

  日期：2009.4.23

  Tricyclic analogues were rationally designed as the high affinity niacin receptor G-protein-coupled receptor 109A (GPR109A) agonists by overlapping three lead structures. Various tricyclic anthranilide and cycloalkene carboxylic acid full agonists were discovered with excellent in vitro activity. Compound 2g displayed a good therapeutic index regarding free fatty acids (FFA) reduction and vasodilation effects in rats, with very weak cytochrome P450 2C8 (CYP2C8) and cytochrome P450 2C9 (CYP2C9) inhibition, and a good mouse pharmacokinetics (PK) profile.
• The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties
  作者：Jason E. Imbriglio、Daniel DiRocco、Rena Bodner、Subharekha Raghavan、Weichun Chen、Daria Marley、Craig Esser、Tom G. Holt、Michael S. Wolff、Andrew K.P. Taggart、M. Gerard Waters、James R. Tata、Steven L. Colletti

  DOI：10.1016/j.bmcl.2010.11.116

  日期：2011.5

  Amino-anthranilic acid derivatives have been identified as a new class of low serum shifted, high affinity full agonists of the human orphan G-protein-coupled receptor GPR109a with improved ADME properties. (C) 2010 Elsevier Ltd. All rights reserved.